Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT)

Cho, Daniel; Blasio, Christopher J. Di; Rhee, Audrey; Kattan, Michael W.

doi:10.1016/s1078-1439(03)00057-7

Cited by 25 publications

(22 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, various clinical and biochemical parameters, as well as tumour characteristics, have been reported to be useful for predicting the survival of patients with metastatic prostate cancer [11]. Clinical and biochemical factors, such as lower PS, pain score, EOD on bone scan, lower pretreatment serum testosterone levels, higher serum ALP and acid phosphatase levels, higher PSA levels, and lower HGB levels, have all been reported to be associated with treatment response or patient survival [12]. Pathological and immunohistochemical studies have also shown that nuclear texture, oligosaccharide sialyl Lewis (x), c-erbB-2 (Her2/neu) and tissue factor could be predictors of survival [13].…”

Section: Discussionmentioning

confidence: 99%

The isolation and identification of apolipoprotein C-I in hormone-refractory prostate cancer using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

Yamamoto-Ishikawa¹,

Suzuki²,

Nezu³

et al. 2009

Asian J Androl

View full text Add to dashboard Cite

Androgens play a central role in prostate cancer pathogenesis, and hence most of the patients respond to androgen deprivation therapies. However, patients tend to relapse with aggressive prostate cancer, which has been termed as hormone refractory. To identify the proteins that mediate progression to the hormone-refractory state, we used protein-chip technology for mass profiling of patients' sera. This study included 16 patients with metastatic hormone-refractory prostate cancer who were initially treated with androgen deprivation therapy. Serum samples were collected from each patient at five time points: point A, pre-treatment; point B, at the nadir of the prostatespecific antigen (PSA) level; point C, PSA failure; point D, the early hormone-refractory phase; and point E, the late hormone-refractory phase. Using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, we performed protein mass profiling of the patients' sera and identified a 6 640-Da peak that increased with disease progression. Target proteins were partially purified, and by amino acid sequencing the peak was identified as a fragment of apolipoprotein C-I (ApoC-I). Serum ApoC-I protein levels increased with disease progression. On immunohistochemical analysis, the ApoC-I protein was found localized to the cytoplasm of the hormone-refractory cancer cells. In this study, we showed an increase in serum ApoC-I protein levels in prostate cancer patients during their progression to the hormone-refractory state, which suggests that ApoC-I protein is related to progression of prostate cancer. However, as the exact role of ApoC-I in prostate cancer pathogenesis is unclear, further research is required.

show abstract

Section: Discussionmentioning

confidence: 99%

The isolation and identification of apolipoprotein C-I in hormone-refractory prostate cancer using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

Yamamoto-Ishikawa¹,

Suzuki²,

Nezu³

et al. 2009

Asian J Androl

View full text Add to dashboard Cite

show abstract

“…Despite significant advances in prostate cancer treatment, the survival rate for advanced stages of this particular cancer has not significantly improved during the past decade (2). The high mortality rate observed in advanced prostate cancer patients is due to loss of androgen dependency for cancer cell growth that results in resistance to androgen ablation therapy (3). Furthermore, standard treatment options for localized prostate cancer (surgical, radiation, and hormonal therapy) are associated with morbidities that often impair patient quality of life, such as urinary incontinence and sexual dysfunction (4).…”

Section: Introductionmentioning

confidence: 99%

Molecular Mechanism of Anti-Prostate Cancer Activity ofScutellaria BaicalensisExtract

Jiang

Volshonok

et al. 2007

Nutrition and Cancer

View full text Add to dashboard Cite

“…For example, ZA administration improved PSA levels in a case of CRPC with bone and lymph nodes metastases (Kikuno et al, 2007). According to Prostate Cancer Nomograms: Hormone Refractory by Memorial Sloan-Kettering Cancer Center, survival probabilities for this patient after 1 and 2 years were estimated to be 73 % and 35 % respectively (median, 18 months) (Cho et al, 2003). However, in our present case relapse-free survival with low PSA levels and reduced lymph nodes were maintained for 3 years after ZA administration.…”

Section: Dear Editormentioning

confidence: 98%

Zoledronic Acid Administration in Aggressive Castration-Resistant Prostate Cancer

Taguchi¹,

Fujimura²,

Kume³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT)

Cited by 25 publications

References 45 publications

The isolation and identification of apolipoprotein C-I in hormone-refractory prostate cancer using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

The isolation and identification of apolipoprotein C-I in hormone-refractory prostate cancer using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

Molecular Mechanism of Anti-Prostate Cancer Activity ofScutellaria BaicalensisExtract

Zoledronic Acid Administration in Aggressive Castration-Resistant Prostate Cancer

Contact Info

Product

Resources

About